MCP Agilent Technologies
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     



This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Glossary
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Li, Z.
Right arrow Articles by Huang, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, Z.
Right arrow Articles by Huang, C.

Submitted on November 12, 2007
Revised on April 1, 2008
Accepted on April 17, 2008

Proteomic identification of cyclophilin A as a potential prognostic factor and therapeutic target in endometrial carcinoma

Zhengyu Li, Xia Zhao, Shujun Bai, Zhi Wang, Lijuan Chen, Yuquan Wei, and Canhua Huang

The State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan 610041

Corresponding Author: hcanhua{at}hotmail.com

Endometrial carcinoma is one of the most common malignancies of the female genital tract, and there is an urgent need for discovery of novel factor for prognostic assessment and therapeutic targets to endometrial carcinoma. Herein, 2-DE and MALDI-Q-TOF MS/MS-based proteomic approach was used to identify differentially expressed proteins in endometrial carcinoma. Of the 99 proteins identified, cyclophilin A was one of the most significantly altered proteins and its over-expression was confirmed using RT-PCR and Western blot analyses. Immunohistochemistry suggested a link between cyclophilin A expression and poor differentiation and decreased survival (P<0.01). Knockdown of cyclophilin A expression by RNA interference led to the significant suppression of the cell growth and the induction of apoptosis in endometrial carcinoma HEC-1-B cells in vitro (P<0.01), and the inhibition of tumor growth in vivo (P<0.01). These data suggest that cyclophilin A may serve as a novel prognostic factor and possibly an attractive therapeutic target for endometrial carcinoma.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.